SR-202 (PPAR Antagonist): Precise Inhibition of PPARγ in Metabolic and Immune Research

Executive Summary: SR-202 (B6929) is a selective antagonist of peroxisome proliferator-activated receptor gamma (PPARγ) used to dissect PPAR signaling in metabolic and immune pathways (APExBIO). It blocks TZD-induced transcriptional activity and coactivator recruitment in vitro, resulting in inhibition of adipocyte differentiation. In vivo, SR-202 reduces high-fat diet-induced adipocyte hypertrophy and improves insulin sensitivity in diabetic mouse models. The compound is chemically stable, highly soluble in DMSO, ethanol, and water, and is best stored desiccated at room temperature. No human clinical trials have been performed to date (Xue et al., 2025).

Biological Rationale

Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor that regulates glucose metabolism, fatty acid storage, and adipocyte differentiation (Xue et al., 2025). PPARγ activation promotes adipogenesis and has pivotal roles in macrophage polarization, balancing pro-inflammatory (M1) and anti-inflammatory (M2) states. Abnormal PPARγ signaling is implicated in type 2 diabetes, obesity, and immune-metabolic crosstalk. Macrophage polarization, influenced by PPARγ, determines tissue inflammation and repair outcome. Selective antagonists like SR-202 offer researchers the ability to inhibit PPARγ activity and directly assess its role in metabolic disease and immune modulation (SR-202: A Selective PPARγ Antagonist Transforming Macrophage Research). This article extends prior analyses by providing detailed, benchmarked parameters and clarifying translational boundaries.

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202, chemically designated as (S)-(4-chlorophenyl)(dimethoxyphosphoryl)methyl dimethyl phosphate (CAS: proprietary), is a white solid with a molecular weight of 358.65 g/mol and formula C11H17ClO7P2. It acts as a selective PPARγ antagonist, targeting the ligand-binding domain and preventing agonist-induced recruitment of coactivators such as steroid receptor coactivator-1 (SRC-1). In vitro, SR-202 suppresses thiazolidinedione (TZD)-stimulated PPARγ transcriptional activity and inhibits PPARγ-dependent adipocyte differentiation in pre-adipocyte cell lines. The compound shows selectivity for PPAR family members over other nuclear receptors, minimizing off-target effects. SR-202 also disrupts hormone-induced adipocyte differentiation in cultured cells. In animal models, SR-202 counteracts high-fat diet-induced adipocyte hypertrophy, reduces insulin resistance, and lowers circulating TNF-α—an inflammatory cytokine elevated in obesity (Xue et al., 2025). For more on the molecular dissection of PPARγ antagonism, see SR-202 (PPAR Antagonist): Unlocking Precision Tools for PPAR Pathways, which this article updates with new benchmarks and application strategies.

Evidence & Benchmarks

• SR-202 selectively blocks TZD-induced PPARγ transcriptional activity, as measured by luciferase reporter assays in pre-adipocyte cultures (DOI:10.1002/kjm2.12927).
• In vitro, SR-202 (≥10 μM, 24–72 h, 37°C, 5% CO2) inhibits PPARγ-dependent adipocyte differentiation, confirmed by Oil Red O staining and gene expression of adipogenic markers (DOI:10.1002/kjm2.12927).
• SR-202 administration in ob/ob mice (dose: 20–40 mg/kg/day, oral gavage, 4 weeks) reduces high-fat diet-induced adipocyte hypertrophy and improves glucose tolerance (GTT) and insulin sensitivity (ITT) assays (DOI:10.1002/kjm2.12927).
• Treatment with SR-202 lowers plasma TNF-α levels in wild-type mice fed a high-fat diet (ELISA, after 4 weeks of treatment) (DOI:10.1002/kjm2.12927).
• SR-202 is soluble at ≥50 mg/mL in DMSO, ethanol, and water. Optimal experimental results are reported when the compound is freshly prepared before use (APExBIO).

Applications, Limits & Misconceptions

SR-202 is a research tool for dissecting PPARγ function in metabolic and immunological models. It is suited for studies of insulin resistance, adipogenesis, and macrophage polarization. SR-202 (PPAR antagonist) enables mechanistic investigation of the PPAR signaling pathway, providing specificity not achieved by non-selective nuclear receptor modulators.

• SR-202 is not approved for human or veterinary therapeutic use; it is strictly for preclinical research.
• No clinical trials have evaluated safety or efficacy in human subjects (APExBIO).
• Long-term storage of SR-202 solutions is not recommended due to potential hydrolysis; dry, desiccated storage is advised.

This article clarifies and updates the practical guidance found in Practical Solutions for Macrophage and Metabolic Studies with SR-202 by providing new, peer-reviewed evidence and solvent handling recommendations.

Common Pitfalls or Misconceptions

• SR-202 does not act as a PPARγ agonist; it is strictly an antagonist.
• SR-202 does not broadly inhibit all nuclear receptors; selectivity is for PPAR family members.
• SR-202 is not a substitute for clinical PPARγ antagonists under investigation for human therapy.
• SR-202 should not be stored in solution for extended periods due to instability.
• No data support use in non-mammalian models; efficacy and selectivity may not extrapolate outside rodent or cell culture systems.

Workflow Integration & Parameters

Preparation: Dissolve SR-202 at ≥50 mg/mL in DMSO, ethanol, or water. Solutions should be freshly prepared and used immediately. For cell-based assays, dilute to working concentrations (commonly 1–50 μM) in culture media. For in vivo studies, prepare dosing solutions according to animal protocol, ensuring homogeneity and avoiding precipitation. Store the powder desiccated at room temperature; do not freeze solutions for long-term storage.

Experimental Design: Use SR-202 to antagonize TZD- or hormone-induced PPARγ activity. Monitor cellular endpoints (adipocyte differentiation, gene expression), metabolic phenotypes (glucose tolerance, insulin sensitivity), and immune readouts (macrophage polarization, TNF-α levels). For protocol optimization and troubleshooting, consult SR-202: Selective PPARγ Inhibition for Adipocyte and Nuclear Receptor Studies, which this article extends with solvent compatibility and new mouse model data.

Vendor Selection: APExBIO is the originating and validated supplier of SR-202 (SKU B6929). For quality control and batch reproducibility, always refer to the latest certificate of analysis and technical datasheet (SR-202 product page).

Conclusion & Outlook

SR-202 is a validated, selective PPARγ antagonist that enables precise interrogation of PPAR signaling in metabolic and immune models. Its unique mechanism, high solubility, and reproducible performance make it an indispensable tool for obesity, diabetes, and immune-metabolic research. As no clinical data exist, its use remains restricted to experimental models. Future studies may extend the utility of SR-202 to new disease models and support anti-obesity drug development. For comprehensive product details and ordering, visit the SR-202 (PPAR antagonist) product page.